EUVIMEDEUVIMED entdecken
Fallbericht

Postoperative recurrence of ROS1-rearranged lung adenocarcinoma: A case series

Ryo Miyata iD, Ryota Sumitomo, Ryo Nakanobo, Masatsugu Hamaji iD

The Thoracic and Cardiovascular Surgeon · 01.08.2026 · 74 (05) · 430-432

DOI: 10.1055/a-2768-2882 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 01.08.2026. Verfasst von Ryo Miyata und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Neoplasm Recurrence, Local, Gene Rearrangement, Adenocarcinoma of Lung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postoperative recurrence of ROS1-rearranged non-small cell lung cancer is rarely reported, and the role of tyrosine kinase inhibitors (TKIs) remains unclear. We retrospectively reviewed four patients with completely resected ROS1-positive lung adenocarcinoma who developed recurrence, three receiving crizotinib. The median disease-free interval was 33.4 months, and median overall survival from postoperative recurrence and initial surgery was 40.7 and 71.2 months, respectively. Brain metastases were the most common initial recurrence site (75%). Crizotinib showed limited efficacy with a median progression-free survival of 3.5 months. These findings highlight indolent disease behavior but limited TKI benefit, supporting the need for adjuvant trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsNeoplasm Recurrence, LocalGene RearrangementAdenocarcinoma of LungProto-Oncogene ProteinsPneumonectomyProtein-Tyrosine KinasesHumansProtein Kinase InhibitorsTime FactorsRetrospective StudiesCrizotinibMaleFemaleMiddle AgedAgedProgression-Free SurvivalTreatment OutcomeGenetic Predisposition to Disease

Substanzen

ROS1 protein, humanProtein Kinase InhibitorsProto-Oncogene ProteinsProtein-Tyrosine KinasesCrizotinib

Autor:innen und Institutionen

  • Department of Thoracic and Cardiovascular Surgery, Nara Medical University, Nara, Japan.
  • Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan.
  • Department of Thoracic Surgery, Kurashiki Central Hospital, Okayama, Japan.

ORCID-Profile: Ryo Miyata, Masatsugu Hamaji

Zitieren

APA

Miyata, R., Sumitomo, R., Nakanobo, R., & Hamaji, M. (2026). Postoperative recurrence of ROS1-rearranged lung adenocarcinoma: A case series. The Thoracic and Cardiovascular Surgeon, 74(05), 430-432. https://doi.org/10.1055/a-2768-2882

Vancouver

Miyata R, Sumitomo R, Nakanobo R, Hamaji M. Postoperative recurrence of ROS1-rearranged lung adenocarcinoma: A case series. The Thoracic and Cardiovascular Surgeon. 2026;74(05):430-432. doi:10.1055/a-2768-2882

BibTeX
@article{Miyata2026,
  author = {Miyata, Ryo and Sumitomo, Ryota and Nakanobo, Ryo and Hamaji, Masatsugu},
  title = {Postoperative recurrence of ROS1-rearranged lung adenocarcinoma: A case series},
  journal = {The Thoracic and Cardiovascular Surgeon},
  year = {2026},
  volume = {74},
  number = {05},
  pages = {430--432},
  doi = {10.1055/a-2768-2882}
}
Kostenlos starten →